Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +1.31%34 3-Year Book Growth Rate is -40.50% as of Jun. 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,128 Biotechnology companies, Solid Biosciences ranks worse than 80.59% on this metric.
During the past 12 months, Solid Biosciences's average Book Value per Share Growth Rate was 6.90% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -40.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -41.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Solid Biosciences was -18.90% per year. The lowest was -50.70% per year. And the median was -35.70% per year.
Solid Biosciences (NAS:SLDB) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Solid Biosciences 3-Year Book Growth Rate Related Terms
SLDB vs AVTX, SLNCF, OBX: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Solid Biosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's 3-Year Book Growth Rate falls into.
Solid Biosciences 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -40.50% mean?
Solid Biosciences (SLDB) has a 3-Year Book Growth Rate of -40.50% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Solid Biosciences and its competitors. According to the industry distribution chart, Solid Biosciences ranks #909 out of 1128 companies in the Biotechnology industry, placing it in the top 80.6%.
Is Solid Biosciences' 3-Year Book Growth Rate too high?
Solid Biosciences' current 3-Year Book Growth Rate is -40.50%. Based on the distribution chart, Solid Biosciences ranks #909 out of 1128 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' 3-Year Book Growth Rate compare to AVTX and SLNCF?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #909 out of 1128 companies for 3-Year Book Growth Rate. This places Solid Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Solid Biosciences and its competitors. Solid Biosciences's current 3-Year Book Growth Rate is -40.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current 3-Year Book Growth Rate of -40.50%. The current 3-Year Book Growth Rate is -40.50%. Solid Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current 3-Year Book Growth Rate is -40.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
